Isomab
Founded 2022 · 15 employees on LinkedIn · 1 known investors
Isomab develops ISM-001, an antibody therapeutic that selectively restores collateral blood vessel growth in the heart under low-oxygen conditions. Its lead indication is stable angina, with preparations underway for first-in-human dosing.
Investors · 1
Frequently asked questions
- What does Isomab do?
- Isomab develops ISM-001, an antibody therapeutic that selectively restores collateral blood vessel growth in the heart under low-oxygen conditions. Its lead indication is stable angina, with preparations underway for first-in-human dosing.
- Who are Isomab's investors?
- Isomab's investors include Broadview Ventures.